Results 171 to 180 of about 74,341 (223)

Exploring the potential of vamotinib in Ph+ leukemias: is it indeed a 3rd generation tyrosine kinase-inhibitor? [PDF]

J Hematol Oncol
Lucini C, Sponseiler I, Bandian AM, Senkiv J, Lion T.   +4 more
europepmc   +1 more source

Molecular study of KIT gene that is related to drug resistance in chronic myeloid leukemia patients. [PDF]

J Genet Eng Biotechnol
Salman AK, Dhamad AE.
europepmc   +1 more source

Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives. [PDF]

Clinicoecon Outcomes Res
Vaughn JE, Zawadzki N, Zhang S, Pinkston P, Wei D, Shafrin J.   +5 more
europepmc   +1 more source

Zero-premium Medicare Advantage plans and access to generic abiraterone and imatinib. [PDF]

Health Aff Sch
Jiang C, Tang Y, Lu CA, Shih YT, Yabroff KR, Han X, Hu X.   +6 more
europepmc   +1 more source

Effectiveness and Safety of Imatinib and Nilotinib in Chronic Myeloid Leukemia: A Single-Center Study From Southern Morocco. [PDF]

Cureus
El Mousadik M, El Khayat H, El Hizazi L, Bounar O, Halloumi O, Fatima Ezzahra R, Chakri I, Bouqoufi A, Lahlou L, Fares S.   +9 more
europepmc   +1 more source

Impact of Imatinib Therapy on Immunometabolism to Promote β-Cell Survival in Diabetes. [PDF]

J Diabetes
Kumar S, Kumari R.
europepmc   +1 more source

Targeting the SETD2-FTO-KIT pathway as a pharmacological strategy for TKI-refractory GIST. [PDF]

Acta Pharm Sin B
Li Z, He J, Cao Z, Zhou S, Zhu Y, Duan Y, Jiang A, Guan Y, Gao J, Tian J, Liu L, Rong Z, Liu H, Liu X, Xiao H, Deng Y, Li B, Sun L.   +17 more
europepmc   +1 more source

Real-World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles Safety-Net Health System: Tyrosine Kinase Inhibitor Treatment Patterns and Outcomes From 2015 to 2024. [PDF]

Cancer Med
Zheng D, Nold T, Ramakrishnan N, Kim K, Tomassetti S.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Imatinib

Drugs, 2001
Imatinib inhibits the BCR-ABL tyrosine kinase created by the Philadelphia chromosome (Ph+) in chronic myeloid leukaemia (CML). Complete haematological responses were achieved in 88% of patients and major cytogenetic responses were detected in 49% of patients with chronic phase CML treated with oral imatinib 400 mg/day in a multicentre noncomparative ...
K, Lyseng-Williamson, B, Jarvis
openaire   +2 more sources